We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Control Cohort CTRL COH (CTRL COH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05370079
Recruitment Status : Not yet recruiting
First Posted : May 11, 2022
Last Update Posted : September 14, 2022
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers.

Condition or disease Intervention/treatment Phase
Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis Biological: Collection of biological sample (blood and/or CSF) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Control Cohort CTRL COH
Estimated Study Start Date : September 16, 2022
Estimated Primary Completion Date : September 16, 2027
Estimated Study Completion Date : September 16, 2027


Arm Intervention/treatment
Control cohort
Patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.
Biological: Collection of biological sample (blood and/or CSF)

Blood sample will be collected one time for each patient:

2 *4ml of blood on dry tube 2 *4ml of blood on EDTA tube

If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).





Primary Outcome Measures :
  1. Samples (blood dry and EDTA tube and optional cerebro-spinal-fluid) [ Time Frame: 15 minutes ]
    Numbers of samples collected and patients included in the cohort


Secondary Outcome Measures :
  1. Description of genetic analysis [ Time Frame: Data collecting: 3 years Data analysis: 2 years ]
    Number of new biomarkers (genetic) and specific HLA (human leucocyte antigen)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patient with consent
  • patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.

Exclusion Criteria:

  • refusal consent
  • patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
  • patient under guardianship

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05370079


Contacts
Layout table for location contacts
Contact: Jerome Honnorat, Pr (33) 4 72 35 78 06 jerome.honnorat@chu-lyon.fr
Contact: Mathilde Millot, CRA (33) 4 72 35 70 58 mathilde.millot@chu-lyon.fr

Locations
Layout table for location information
France
Hospices Civils de Lyon
Bron, France, 69500
Contact: Jerome HONNORAT, Pr    (33) 4 72 35 78 06    jerome.honnorat@chu-lyon.fr   
Principal Investigator: Jerome HONNORAT         
Sponsors and Collaborators
Hospices Civils de Lyon
Investigators
Layout table for investigator information
Principal Investigator: Jerome Honnorat, Pr Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Lyon, France
Layout table for additonal information
Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT05370079    
Other Study ID Numbers: 69HCL22_0275
First Posted: May 11, 2022    Key Record Dates
Last Update Posted: September 14, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hospices Civils de Lyon:
Biological collection, control cohort,, new biomarkers
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Arthritis
Parkinson Disease
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Nervous System Diseases
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuromuscular Diseases
Spinal Cord Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Joint Diseases
Musculoskeletal Diseases